small molecule glp-1 receptor agonist Structural insights into the activation of GLP-1R by a Design, Synthesis, and Pharmacological Evaluation

Common GLP-1 medications prescribed in 2025 include: Semaglutide (Wegovy, Ozempic) Tirzepatide (Mounjaro) Liraglutide (Saxenda) Peer-reviewed clinical trials published in journals such as The New England Journal of Medicine and JAMA document average body weight reductions of approximately 1022% over 612 months when GLP-1 medications are combined with lifestyle support and ongoing physician oversight

doi: 10.1093/eurheartj/ehae568 53

[DOI] [PMC free article] [PubMed] [Google Scholar] 29.Stretton B., Kovoor J., Bacchi S., Chang S., Ngoi B., Murray T., Bristow T.C., Heng J., Gupta A., Ovenden C., et al

Color of Product Tirzepatide/Glycine/B12* is a light pinkish product due to the addition of B12

Understanding those differences is key to choosing what actually fits your body, lifestyle, and long-term goals

The SGLT2i treated cohort experienced higher rates of diabetic ketoacidosis (DKA) (RR 2.08 [95% CI 1.05, 4.12] p =0.0309) and urinary tract infection/pyelonephritis (RR 2.27 [95% CI 1.12, 4.55] p =0.019) compared with the GLP-1 RA treated cohort